Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers

Nes-Ziona, Israel, March 20, 2023 -- Enlivex Therapeutics Ltd. , a clinical-stage macrophage reprogramming immunotherapy company, today announced that an independent Data and Safety Monitoring... | March 20, 2023

Related Keywords

Israel ,Israeli ,Eric Ribner ,Shachar Shlosberger ,Einat Galamidi ,Exchange Commission ,Israeli Ministry Of Health ,Enlivex Therapeutics Ltd ,Nasdaq ,Safety Monitoring Board ,Israeli Ministry ,Medical Vice President ,Harbor Statement ,Private Securities Litigation Reform Act ,Annual Report ,Enlivex Therapeutics Ltd Stock Exchange ,News ,Information ,Press Release ,Arch ,023 ,Enlivex ,Herapeutics ,Acrophage ,Deprogramming ,Immunotherapy ,Oday ,Nnounced ,Hat ,N ,Independent ,Data ,End ,Afety Enlv Il0011319527 ,